Antimalarials may influence the risk of malignancy in systemic lupus erythematosus

Annals of the Rheumatic Diseases

Volumn 66, Issue 6, 2007, Pages 815-817

  Ruiz Irastorza, G ^a,b   Ugarte, A ^a   Egurbide, M V ^a   Garmendia, M ^a   Pijoan, J I ^a   Martinez Berriotxoa, A ^a   Aguirre, C ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; METHOTREXATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; ANTIMALARIALS; ANTINEOPLASTIC AGENTS; ANTIRHEUMATIC AGENTS; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; NEOPLASMS;

EID: 34249801215     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.067777     Document Type: Article

References (15)

1. Bernatski S, Ramsey-Goldman R, Clarke A. Exploring the links between systemic lupus erythematosus and cancer. Rheum Dis Clin North Am 2005;31:387-402.
2. Bernatski S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005;52:1481-90.
3. Moss KE, Ioannou Y, Sultan SM, Haq I, Isenberg DA. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 2002;61:409-13.
4. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, Garmendia M, Villar I, Martinez-Berriotxoa A, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006;15:577-83.
5. Sotelo J, Briceño E, López-González MA. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double blind, placebo-controlled trial. Ann Intern Med 2006;144:337-43.
6. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
7. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The systemic lupus erythematosus international collaborating clinics/American College of Rheumatology index for systemic lupus erythematosus international comparison. J Rheumatol 2000;27:373-6.
8. Sultan SM, Ioannou Y, Isenberg DA. Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology 2000;39:1147-52.
9. Cibere J, Sibley J, Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus 2001;10:394-400.
10. Fessler BS, Alarcón GS, McGwin Jr G, Roseman J, Bastion HM, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups XVI: hydroxychloroquine usage is associated with a lower risk of damage accrual. Arthritis Rheum 2005;52:1473-80.
11. Alarcón GS, McGwin G Jr, Fessler BJ, Bertoli AM, Calvo-Alén J, Bastion HM, et al. "Confounding by indications" partially explains the protective effect of hydroxychloroquine (HCQ) in SLE survival: data from a multiethnic US cohort. Arthritis Rheum 2005;52:S726.
12. Wallace DJ. Antimalarials agents and lupus. Rheum Dis Clin North Am 1994;20:243-63.
13. Sohn TA, Bansal R, Su GH, Murphy KM, Kern SE. High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter. Carcinogenesis 2002;23:949-57.
14. Riccio ES, Lee PS, Winegar RA, Krogstad DJ, De D, Mirsalis JC. Genetic toxicology testing of the antimalarial drugs chloroquine and a new analog, AQ-13. Environ Mol Mutagen 2001;38:69-79.
15. Briceno E, Reyes S, Sotelo J. Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurg Focus 2003;14:e3.